Funding information

Doctoral
Amount: $22,000/year Duration: 3 years
Eligibility: Within first 18 months of PhD program

Postdoctoral
Amount: $50,00/year (PhD) | $50,00/year (MD) Duration: 2 years
Eligibility: Within 18 months of obtaining PhD (extension may be given to MDs)

New Investigator Operating Grant
Amount: $200,000 Duration: Up to 4 years
Eligibility: Within the first 4 years of initial faculty position

Proof of Concept Grant
Amount: $100,000 Duration: Up to 5 years
Eligibility: Must hold a faculty position with a Canadian university or affiliated institution

The Canadian Hemophilia Society (CHS) put out its first call for applications for its research programs for the 2020-2021 grant period on August 29 but since then, we have received the confirmation that the Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program will be funded again. We are therefore pleased to add this research program to the ones you may consider applying for. The deadline to submit applications for all the programs is November 15, 2019. The eligibility criteria and conditions for all our research programs have been revised and updated. Of note, eligibility has been expanded as follows:

Ø  Dream of a Cure: the program is no longer limited to hemophilia A & B-related projects so that projects focusing on von Willebrand disease, rare factor deficiencies, platelet function disorders (and platelet pathophysiology) and other congenital and acquired bleeding disorders can be supported;

Ø  Dream of a Cure Studentships in Inherited Bleeding Disorders Research: similarly to our basic scientific research program, the studentships are no longer limited to hemophilia-related projects but include all inherited bleeding disorders. Furthermore, science students in any year of an undergraduate program can apply in addition to medical students in any year of training;

Ø  CHS/Pfizer Care Until Cure Research Program: the areas of interest to which investigators are encouraged to submit proposals has been expanded to include mild hemophilia A and B and Factor Utilization & Cost-effectiveness; all projects included but not limited to the list will be considered;

Ø  CHS/Novo Nordisk Psychosocial Research Programme: applications from Social Workers, Nurses, or Physiotherapists with professional experience in a hemophilia treatment centre (or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders) or persons interested in the field of inherited bleeding disorders will be considered. Students in a PhD program in one of the allied health disciplines may also apply. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Professional experience in a hemophilia treatment centre is desirable but not required.

Ø  CHS/Bayer ADVANCE Canada Research Program:  applicant must be a physician or Ph.D. with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. The proposed research must have relevance to current practice in bleeding disorders care and may incorporate a broad spectrum of quantitative and qualitative research methods addressing professional practice with individuals, families, groups and communities, organizational issues, public health, and education.The research studies should aim to provide better data and tools to help the treaters assist patients in successful ageing.

DREAM OF A CURE

Through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders and ultimately, finding a cure.

Dream of a Cure, the CHS Research Program and the 2020 Dream of a Cure Summer Studentships in Inherited Bleeding Disorders Research application forms as well as the general criteria and conditions are available by accessing the CHS Web site at https://www.hemophilia.ca/chs-dream-of-a-cure-research-program/. For Dream of a Cure, individual grants will be awarded to researchers for one to two years for amounts up to $75,000 per year while support will be offered to interested Canadian medical or science students for up to 4 months for a maximum stipend of $6,000 per student. 

______________________________

CHS / PFIZER CARE UNTIL CURE RESEARCH PROGRAM

You will find at https://www.hemophilia.ca/the-chspfizer-care-until-cure-research-program/ the information for the CHS/Pfizer Care until Cure Research Program offered by the CHS in collaboration with Pfizer Canada. This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders. Grants for one to two years with a maximum of $75,000 per year will be awarded for clinical research, including outcome evaluation, in fields relevant to improving the health and the quality of life for persons with Hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.

 
______________________________

CHS/NOVO NORDISK CANADA PSYCHOSOCIAL RESEARCH PROGRAMME

The CHS/Novo Nordisk Canada Psychosocial Research Program was created to engage hemophilia program professionals/graduate students from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.

The primary intent of this program is to offer one or two $20,000 research grants, to a maximum of $40,000 for one year.

Depending upon the number and quality of applications, funding for more than two research grant could be offered within the allotted total budget stated above.

The major portion of each grant would be to cover the research time for the successful candidate(s), including the time for research assistants. A small amount can be devoted to project expenses.

Multidisciplinary Collaboration:
Collaboration with multidisciplinary care providers and/or between two or more hemophilia centres is accepted and encouraged. Collaboration efforts may include, for example, social work, physical therapy and genetics. It thus may be possible for a hemophilia centre team to jointly submit a cooperative research project. Additionally, inter-regional applications will be considered.
 
Applications and Deadline:
A letter of intent should be submitted to the Canadian Hemophilia Society by November 15, 2019. The letter, with a maximum of two pages, should identify the researcher, the organization and include a summary description of the intended area of research.

The CHS Peer Review Committee will invite a limited number of candidates to submit a more detailed proposal by January 17, 2020 in order to make a final selection. Grants will be offered for a one-year period to begin in April 2020.

More detailed information is available by accessing the CHS Web site at https://www.hemophilia.ca/the-chsnovo-nordisk-psychosocial-research-program/

______________________________

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.

The research program will support studies that aim to:

•             Identify and provide insight into key issues associated with the ageing hemophilia population

•             Identify how management of age-related co-morbidities should be adapted to those with hemophilia

•             Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia

The primary intent of this program is to offer one or two $30,000 research grants, to a maximum of $60,000 for one year.

Applications and Deadline:
All completed application forms and support documents must arrive at the National Office of the Canadian Hemophilia Society on or before November 15, 2019.

Should a candidate wish to have the ADVANCE Canada Steering Committee review the application prior to submitting it to the CHS, please provide by e-mail a copy of the application to Robert Martone of Glia Scientific Communication at rmartone@gliasc.com . He will act as your liaison with the Steering Committee.

Additional information, the eligibility criteria and conditions for the research program as well as the application form can be found on our website at this link:

https://www.hemophilia.ca/research-chs-bayer-advance-canada-research-program/

The EUREKA SMART Cluster will launch its third call for proposals for Research, Development, and Innovation (R&D&I) projects on September 9, 2019. SMART is a flexible, industry-driven EUREKA Cluster program whose aim is to promote collaborative, international, and close-to-market R&D&I projects in advanced manufacturing.

Open to: Small and medium-sized enterprises (NRC IRAP funding possible), large firms, universities, and research centres.

Sector of focus: Advanced manufacturing

Key technology application areas:

• Advanced manufacturing processes
• Customer-based manufacturing
• Digital, virtual, and efficient companies
• Intelligent and adaptive manufacturing systems
• Person-machine collaboration
• Sustainable manufacturing

Deadline for Project Outline: November 11, 2019

More information: 2019 EUREKA SMART call for proposals

Manufacturing the cutting edge products that enable the deployment of 5G at volume requires Ciena to to develop innovative solutions for their own supply chain and raise the bar towards Industry 4.0 also known as Smart Manufacturing. Ciena is interested in researching and piloting the usage of augmented reality glasses in the manufacturing and operations support environment. As Ciena’s manufacturing volumes ramp across multiple products, variants, and across multiple contract manufacturers in different geographies, it will be important to leverage technology to connect teams, increase accessibility to context and time senstive information, and find ways to help upskill and guide our operators.

Canadian Blood Services is pleased to announce its 2019 Graduate Fellowship Program competition. Through this exciting Program, Canadian Blood Services offers stipend support for young investigators who want to initiate or continue training in the field of transfusion science. Graduate students undertaking full-time research training in a Canadian institution are invited to apply.

For detailed information about the Graduate Fellowship Program, please refer to www.blood.ca. The deadline to submit completed application packages is November 29 2019.

CANARIE, a vital component of Canada’s digital research infrastructure (DRI) ecosystem supporting research, education and innovation, today announced two separate Calls for Proposals to fund software that supports the complete research workflow: data acquisition, storage, computation/processing, visualization, and data management.

Elements of the research workflow are common across all research disciplines. Similarly, data gathered by one researcher can be leveraged by other researchers, even in different disciplines. By supporting and promoting the re-use of software platforms and research data, public investments in science are maximized: research funding is allocated to research, rather than the development of software that already exists, and collected data can be re-used by other researchers, through interconnected and interoperable repositories and systems.

Today’s funding announcement aims to strengthen Canadian leadership in research in two ways: by funding software development aimed at the reuse of existing research software platforms, and by facilitating the reuse and management of research data.

• Research Software Program funding will support research teams who will adapt existing research platforms for re-use by new research teams.
• Research Data Management (RDM) Program funding will support collaborative interoperability and integration of data repositories and systems within Canadian and global digital research infrastructures (DRI).

Canadian research teams are invited to apply to one or both funding calls. 

Research Data Management Program Funding Call

Detailed information on this call including eligibility requirements, project milestones, and application resources can be found at: canarie.ca/rdm/call2

Key Dates

• Information webinars:

• September 13, 2019 at 1:30 pm ET | Register: canarie.ca/rdm-webinar1
• September 20, 2019 at 1:00 pm ET | Register: canarie.ca/rdm-webinar2

• Proposal submission deadline: October 29, 2019 – 1:00 pm ET

CANARIE, a vital component of Canada’s digital research infrastructure (DRI) ecosystem supporting research, education and innovation, today announced two separate Calls for Proposals to fund software that supports the complete research workflow: data acquisition, storage, computation/processing, visualization, and data management.

Elements of the research workflow are common across all research disciplines. Similarly, data gathered by one researcher can be leveraged by other researchers, even in different disciplines. By supporting and promoting the re-use of software platforms and research data, public investments in science are maximized: research funding is allocated to research, rather than the development of software that already exists, and collected data can be re-used by other researchers, through interconnected and interoperable repositories and systems.

Today’s funding announcement aims to strengthen Canadian leadership in research in two ways: by funding software development aimed at the reuse of existing research software platforms, and by facilitating the reuse and management of research data.

• Research Software Program funding will support research teams who will adapt existing research platforms for re-use by new research teams.
• Research Data Management (RDM) Program funding will support collaborative interoperability and integration of data repositories and systems within Canadian and global digital research infrastructures (DRI).

Research Software Program Funding Call

Detailed information on this call including eligibility requirements, project milestones, and application resources can be found at: canarie.ca/software/call3

Key Dates

• Information webinars:

• September 19, 2019 at 1:00 pm ET | Register: canarie.ca/rs-webinar1
• October 7, 2019 at 1:00 pm ET | Register: canarie.ca/rs-webinar2

• Proposal submission deadline: November 28, 2019 – 1:00 pm ET

JOHN G. DIEFENBAKER AWARD
The John G. Diefenbaker Award allows a distinguished German scholar in the humanities to conduct research in Canada and spend brief periods gaining further experience at American institutions.  

• Value: Up to $95,000
• Nominating process: Nominations must be made by a department of the host university or research institute. A nomination form must be completed and submitted by mail to the Canada Council for the arts. (Note: The Council’s online portal is not open to prize competitions.)
• Deadline: November 1^st, 2019
• For further information, please refer to the guidelines.

The FY19 Defense Appropriation provides $15 million (M) to the Department of Defense Combat Readiness – Medical Research Program (CRRP) to support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service members in current and future battlefield settings.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Broad Agency Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The Congressional language for the CRRP encompasses research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma.  FY19 CRRP Broad Agency Announcement and General Submission Instructions for the following award mechanism are posted on the Grants.gov website.

FY19 CRRP will solicit research applications addressing at least one of the Focus Areas described below.  The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations, and for delivering medical damage control capability, assets, and life-saving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury.

Applications submitted to the FY19 CRRP must address at least one of the following four Focus Areas:

• Scalable solutions for wound care that can address prevention of bleeding, infection, and acute pain; delivery of therapeutics (including non-opioid solutions for pain); and promotion of healing
• Decision-support solutions, such as algorithms, artificial intelligence, deep learning, and/or telemedicine, for triage and management of severely injured Warfighters, to include management and monitoring of:

o   Hemorrhage and resuscitation (i.e., airway management, control of bleeding, sedation, etc.)

o   Acute pain

o   Multi-casualty events when delayed evacuation exceeds available capability and/or capacity, in order to extend provider capabilities

• Solutions that address hemorrhage control, including:

o   Non-compressible torso hemorrhage

o   Alternatives to optimize logistics and administration of blood products to the Warfighter

• Wearable sensors with broader multiple capabilities to identify and monitor medical management of injuries, to include:

o   Environmental exposures

o   Onset of infection, including sepsis

o   Physiological status (heart rate, blood pressure, respiration), stress monitoring tools

o   Neurological injury

o   Point-of-care imaging

Additional concurrent research approaches that address mitigation of long-term physical and psychological complications that occur from poor management of trauma pain and trauma care, as well as treatments for sepsis and new therapies for multidrug-resistant pathogens, including applications to sepsis, wound care, and injuries incurred outside the battlefield are encouraged, but not required.

https://cdmrp.army.mil/funding/crrp

Rapid Development and Translational Research Award – Letter of Intent due October 23, 2019

• Independent investigators at all academic levels (or equivalent)
• Proposals/applications must be submitted through an extramural organization
• Intramural investigators may be names as a collaborator on a proposal/application submitted through an extramural organization
• Supports new ideas that represent military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Warfighters in current and future battlefield setting. The mechanism is not intended to support fundamental basic research.
• Primary emphasis will be placed on the potential impact of the proposed work.
• Preclinical research supported by substantial preliminary or published data that validates clinical translation is appropriate for this mechanisms.
• Clinical trials are not allowed.
• Must address at least one of the FY19 CRRP Focus Areas.

• Maximum funding of $1,500,000 for direct costs (plus indirect costs)

• Maximum period of performance is 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Broad Agency Announcement and General Submission Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Broad Agency Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the CRRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507 
help@eBrap.org